OncoGenomX AG

OncoGenomX is developing PredictionStar DX, a multimodal precision-oncology platform for HR-positive, HER2-negative metastatic breast cancer that predicts regimen-specific benefit from a single integrated readout. This already-validated platform (2,600 ER patients, three patented classifiers) is positioned for in-house deployment at the U.S. Veterans Affairs network. The current raise funds regulated rollout, scale?up, and milestones toward revenue, reimbursement expansion, and strategic exit options (based on OncoGenomX Company Profile 2026, available upon request).